Atirmociclib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Atirmociclib
- Molecular weight
- 463.94
- Structure (SMILES)
- CC(C)n1c(C(C)(C)O)nc2c(F)cc(-c3nc(N[C@@H]4CCOC[C@H]4O)ncc3Cl)cc21
- atirmociclib
- Atirmociclib
- atirmociclib (PF-07220060)
- atirmociclib [INN]
- ATIRMOCICLIB [USAN]
- Atirmociclib [WHO-DD]
- atirmociclib inn
- atirmociclib usan
- atirmociclib who dd
- Oral PF-07220060
- pf 07220060
- Pf-07220060
- PF-07220060
- PF-07220060 100mg
- PF-07220060 300 mg
- pf07220060
- PF07220060
- CAS registry numbers
- 2380321-51-5
- ChEMBL ID
- CHEMBL5187755
- InChIKey
- QYJLBHRAPDJOSO-NVXWUHKLSA-N
- PubChem compound IDs
- 146219790
- FDA ingredient codes (UNII)
- S743GOJ5LJ
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- atirmociclib
- Type
- Synthetic organic
- Drug name stem
- -ciclib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- cyclin dependent kinase 4
- Gene symbol
- CDK4
- Protein identifier
- P11802
- Median affinity
- 9.22
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- cyclin dependent kinase 6
- Gene symbol
- CDK6
- Protein identifier
- Q00534
- Median affinity
- 7.86
- Affinity units
- pKi
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition identifier
- EFO_0000569
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005060
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006244
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- NCT06206837
- NCT06465368
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 3
- Polar surface area
- 105.32
- Calculated partition coefficient (ALogP)
- 3.66
- Calculated partition coefficient (XLogP)
- 2.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 32
- Molecular formula
- C22H27ClFN5O3
- Monoisotopic mass
- 463.1786456
- Natural product
- No
- Recorded assays
- 85
- Active assays
- 23
Active assay types
- Confirmatory
Related records
Trials (18)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
- A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
- A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
- A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease
- A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060
- A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
- Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
- Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
In development for (4)
- Breast cancer Phase 2
- Liposarcoma Phase 1
- Neoplasm Phase 1
- Prostate cancer Phase 1